So, in this study, we designed and constructed a series of different amino acid mutants from survivin (TmSm34, TmSm48, TmSm84, TmSm34/48, TmSm34/84, and TmSm34/48/84) fused cell-permeable peptide TATm at the N-terminus, and systematically analyzed the anti-cancer viability of various TmSm proteins in vitro for discovering a dominant negative mutant with stronger pro-apoptotic activity to cancer cells. The gene discussed is BIRC5; the disease is cancer.